COVID-19 in a country with a very high prevalence of diabetes: The impact of admission hyperglycaemia on mortality
| Autor: | Lourdes Basurto, Carlos Martínez-Murillo, Rodrigo Rivera Tapia, Karen Pellón, Monica Bejarano Rosales, Christian Omar Ramos Peñafiel, Eder Natanael Flores López, Mercedes Estefania Ledesma, Gilberto Israel Barranco Lampón, Beatriz Li Gómez, Juan Francisco Zazueta, Elizabeth Madera Maldonado, Lourdes Balcázar-Hernández |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Blood Glucose
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment Disease Diseases of the endocrine glands. Clinical endocrinology COVID‐19 Internal medicine Diabetes mellitus Original Research Articles Diabetes Mellitus Medicine Humans In patient Original Research Article Survival rate Mechanical ventilation High prevalence diabetes business.industry digestive oral and skin physiology nutritional and metabolic diseases COVID-19 medicine.disease RC648-665 mortality Clinical trial Survival Rate Hyperglycemia business hyperglycaemia |
| Zdroj: | Endocrinology, Diabetes & Metabolism Endocrinology, Diabetes & Metabolism, Vol 4, Iss 3, Pp n/a-n/a (2021) |
| ISSN: | 2398-9238 |
| Popis: | Aims To evaluate the frequency of diabetes and admission hyperglycaemia in Mexican COVID‐19 patients, to describe the clinical and biochemical characteristics of patients with admission hyperglycaemia and to determinate the impact of diabetes and admission hyperglycaemia on COVID‐19 severity and mortality. Methods A multicentric study was performed in 480 hospitalized patients with COVID‐19. Clinical and biochemical characteristics were evaluated in patients with admission hyperglycaemia and compared with non‐hyperglycaemic patients. The effect of diabetes and admission hyperglycaemia on severity and risk of death were evaluated. Results Age was 50.7 ± 13.6 years; 68.3% were male. Some 48.5% (n = 233) had admission hyperglycaemia; 29% (n = 139) of these patients had pre‐existing diabetes. Patients with admission hyperglycaemia had more requirement of invasive mechanical ventilation (IMV), higher levels of urea, D‐dimer and neutrophil‐lymphocyte ratio (NLR), as well as lower lymphocyte count. An association between admission hyperglycaemia with IMV and D‐dimer with glucose was found. Age ≥50 years (OR 2.09; 95%CI 1.37–3.17), pre‐existing diabetes (OR 2.38; 95%CI 1.59–5.04) and admission hyperglycaemia (OR 8.24; 95%CI 4.74–14.32) were risk factors for mortality. Conclusions Admission hyperglycaemia is presented in 48.5% of COVID‐19 patients. Diabetes and admission hyperglycaemia are associated with the severity of disease and mortality. This study shows the devastating conjunction of hyperglycaemia and COVID‐19. Clinical trial registration: Clinical characteristics of patients with COVID‐19, DI/20/204/04/41 (Hospital General de Mexico) and NR‐13‐2020 (Hospital Regional de Alta Especialidad Ixtapaluca). ‐Diabetes and admission hyperglycaemia are risk factors in severity and mortality among COVID‐19 patients. Patients with pre‐existent diabetes and hyperglycaemia showed an OR 8.24 (95%CI 4.74–14.32) for mortality.‐The results of present study denote the devastating conjunction of two pandemics, diabetes and COVID‐19, in a country with a very high prevalence of metabolic diseases.‐Early detection of hyperglycaemia in patients with COVID‐19, both with and without diabetes, timely treatment and the restoration of normoglycaemia are essential. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text